The second Pan-European multi-stakeholder colloquium

Political lobbying; is there a place for it in the management of MS. #MSBlog #MSResearch 

"How do you feel about political lobbying? I have been invited to speak at the 2nd Pan-European multi-stakeholder colloquium in Brussels this weekend. You can review the programme, which is online. The focus of the meeting will be on accelerating adoption of innovation for better care. Different working groups are exploring potential solutions to address the following key questions:

1. How to stimulate innovation in MS?
2. The roadmap for adopting innovation in biomarkers in MS?
3. The roadmap for creating access to specialized care & patient activation in MS?
4. Can market authorization (MA) policies and HTA drive access & innovation in MS?
5. Creating affordable care for chronic diseases: is MS different?

The outputs from the meeting will hopefully stimulate debate and commitment from politicians to shape EU health policy in relation to MS. The document below is the output of last year's meeting; a call to action. At this year's meeting I have been asked to speak on optimizing the multi-disciplinary approach. I am basing my talk on my holistic approach to MS. You will see in call 9 below (page 18) they group asks for implementation of specialised care centres. I personally have a problem with this specific call in that the whole movement in the NHS is away from hospital-based care (specialised centres) in favour of MSer or patient focused care in the community. In particular with the adoption of new technologies there are already new ways of doing things to optimise the delivery of healthcare to patients. The meeting is going to be an interesting one. I would be interested in your take on specialised centre vs. community-based vs. eMedicine delivered healthcare to treat and manage MS."

Labels: ,